Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer

A randomized phase 2 clinical trial has recently shown no benefit of the combination eribulin and pembrolizumab over pembrolizumab alone in HR + metastatic breast cancer patients (NCT03051659). Here, the authors are reporting the final OS data and biomarker analyses on a subset of samples to analyze...

Full description

Saved in:

Bibliographic Details
Main Authors:	Tanya E. Keenan, Jennifer L. Guerriero, Romualdo Barroso-Sousa, Tianyu Li, Tess O’Meara, Anita Giobbie-Hurder, Nabihah Tayob, Jiani Hu, Mariano Severgnini, Judith Agudo, Ines Vaz-Luis, Leilani Anderson, Victoria Attaya, Jihye Park, Jake Conway, Meng Xiao He, Brendan Reardon, Erin Shannon, Gerburg Wulf, Laura M. Spring, Rinath Jeselsohn, Ian Krop, Nancy U. Lin, Ann Partridge, Eric P. Winer, Elizabeth A. Mittendorf, David Liu, Eliezer M. Van Allen, Sara M. Tolaney
Format:	article
Language:	EN
Published:	Nature Portfolio 2021
Subjects:	Science Q
Online Access:	https://doaj.org/article/d25f24d7eb06482f96ec27595b0111bc
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer

Similar Items